Steeve Provencher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Steeve Provencher has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Marc Humbert
INSERM UMR_S 999, Assistance Publique Hôpitaux de Paris, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre, Université Paris–Saclay , Le Kremlin Bicêtre
4 shared publications - Olivier Sitbon
Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France
4 shared publications - Xavier Jaïs
Université Paris-Saclay, Inserm UMR_S 1358 (HPPIT), Department of Respiratory and Intensive Care Medicine (FHU André Cournand, ERN-LUNG), Hôpital Bicêtre (AP-HP), Le Kremlin Bicêtre, France
3 shared publications - Adam Torbicki
Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre Otwock, Otwock, Poland
2 shared publications G. Simonneau
2 shared publications- Gerald Simonneau
Hôpital de Bicêtre, Univ. Paris-Sud
2 shared publications
Latest Publications
- 1 October 2014
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 30 (10) , S124
EFFECT OF MACITENTAN ON HEMODYNAMICS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: Results FROM THE LONG-TERM, RANDOMISED, PLACEBO-CONTROLLED SERAPHIN TRIAL
- 1 October 2014
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 30 (10) , S124
EFFECT OF MACITENTAN ON HEMODYNAMICS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION: Results FROM THE LONG-TERM, RANDOMISED, PLACEBO-CONTROLLED SERAPHIN TRIAL
- 2 March 2009
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 63 (S 01) , V357
Stress-Doppler-echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia
Background: This large prospective multicentric study was performed to analyse the distribution of tricuspid regurgitation velocity (TRV) values during exercise and hypoxia in relatives of patients with idiopathic (I) and familial (F) pulmonary arterial hypertension (PAH) and in healthy controls. We tested the hypothesis that relatives of I/FPAH patients display an enhanced frequency of hypertensive TRV response to stress and that such response is associated with mutations in the bone morphogenetic protein receptor II (BMPR2) gene. Methods: TRV was estimated by Doppler-echocardiography during supine bicycle exercise in normoxia and during 120 minutes of normobaric hypoxia (Fi02=12% ˜ 4.500m) in 291 relatives of 109 PAH patients and in 191 age- matched controls. Results: Mean maximal TRVs were significantly higher in PAH relatives during both exercise and hypoxia. During exercise, 10% of controls but 31.6% (pBMPR2 gene, a hypertensive TRV response occurred significantly more often compared to those without detected mutations. Conclusions: Pulmonary hypertensive response to exercise and hypoxia in I/FPAH relatives appears as a genetic trait with familial clustering, being correlated with but not caused by a BMPR2 mutation. The suitability of this trait to predict manifest PAH development is to be addressed in long term follow up studies. The study was funded by a grant of the European Union, 5th framework program: „Disposition to PPH, QLG1-CT-2002–01116“
- 2 March 2009
- Published by Georg Thieme Verlag KG in Pneumologie
- Vol. 63 (S 01) , V357
Stress-Doppler-echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia
Background: This large prospective multicentric study was performed to analyse the distribution of tricuspid regurgitation velocity (TRV) values during exercise and hypoxia in relatives of patients with idiopathic (I) and familial (F) pulmonary arterial hypertension (PAH) and in healthy controls. We tested the hypothesis that relatives of I/FPAH patients display an enhanced frequency of hypertensive TRV response to stress and that such response is associated with mutations in the bone morphogenetic protein receptor II (BMPR2) gene. Methods: TRV was estimated by Doppler-echocardiography during supine bicycle exercise in normoxia and during 120 minutes of normobaric hypoxia (Fi02=12% ˜ 4.500m) in 291 relatives of 109 PAH patients and in 191 age- matched controls. Results: Mean maximal TRVs were significantly higher in PAH relatives during both exercise and hypoxia. During exercise, 10% of controls but 31.6% (pBMPR2 gene, a hypertensive TRV response occurred significantly more often compared to those without detected mutations. Conclusions: Pulmonary hypertensive response to exercise and hypoxia in I/FPAH relatives appears as a genetic trait with familial clustering, being correlated with but not caused by a BMPR2 mutation. The suitability of this trait to predict manifest PAH development is to be addressed in long term follow up studies. The study was funded by a grant of the European Union, 5th framework program: „Disposition to PPH, QLG1-CT-2002–01116“
- 1 January 2006
- Published by Elsevier in Gastroenterology
- Vol. 130 (1) , 120-126
Deleterious Effects of β-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension
- 1 January 2006
- Published by Elsevier in Gastroenterology
- Vol. 130 (1) , 120-126
Deleterious Effects of β-Blockers on Exercise Capacity and Hemodynamics in Patients With Portopulmonary Hypertension
- Open Access
- 1 January 2006
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 27 (1) , 114-120
Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension
Patients with pulmonary arterial hypertension (PAH) exhibit a limited increase in stroke volume on exercise, and the heart rate (HR) increases may reflect the main mechanism that allows cardiac output to increase. The current prospective study documented the contribution of HR to the 6-min walking distance (6MWD) in idiopathic (IPAH) and nonidiopathic PAH.Eighty-three patients (46 IPAH and 37 nonidiopathic PAH) underwent haemodynamic evaluation and a 6MWD test. Chronotropic response (peak walking HR minus resting HR) and peripheral oxygen saturation were monitored. Fifty-seven patients were also assessed after 5±2 months of treatment (bosentan n = 38, epoprostenol n = 14, bosentan-epoprostenol n = 3, iloprost n = 2).Before treatment, the 6MWD was related to numerous demographic, haemodynamic and walking test characteristics. Stepwise regression analysis indicated that the only factors significantly associated with the 6MWD were stroke volume and chronotropic response in both IPAH and nonidiopathic PAH patients. Following treatment, changes in 6MWD were significantly related to changes in chronotropic response in both IPAH and nonidiopathic PAH.In conclusion, baseline stroke volume and chronotropic response were independently associated with the 6-min walking distance in pulmonary arterial hypertension. The lack of chronotropic response may reflect the loss in normal physiological reserve in more unwell patients.
- 1 January 2006
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 27 (1) , 114-120
Open AccessHeart rate responses during the 6-minute walk test in pulmonary arterial hypertension
Patients with pulmonary arterial hypertension (PAH) exhibit a limited increase in stroke volume on exercise, and the heart rate (HR) increases may reflect the main mechanism that allows cardiac output to increase. The current prospective study documented the contribution of HR to the 6-min walking distance (6MWD) in idiopathic (IPAH) and nonidiopathic PAH.Eighty-three patients (46 IPAH and 37 nonidiopathic PAH) underwent haemodynamic evaluation and a 6MWD test. Chronotropic response (peak walking HR minus resting HR) and peripheral oxygen saturation were monitored. Fifty-seven patients were also assessed after 5±2 months of treatment (bosentan n = 38, epoprostenol n = 14, bosentan-epoprostenol n = 3, iloprost n = 2).Before treatment, the 6MWD was related to numerous demographic, haemodynamic and walking test characteristics. Stepwise regression analysis indicated that the only factors significantly associated with the 6MWD were stroke volume and chronotropic response in both IPAH and nonidiopathic PAH patients. Following treatment, changes in 6MWD were significantly related to changes in chronotropic response in both IPAH and nonidiopathic PAH.In conclusion, baseline stroke volume and chronotropic response were independently associated with the 6-min walking distance in pulmonary arterial hypertension. The lack of chronotropic response may reflect the loss in normal physiological reserve in more unwell patients.
- 1 November 2005
- Published by Elsevier in La Presse Médicale
- Vol. 34 (19) , 1435-1444
Diagnostic et classification des hypertensions artérielles pulmonaires
- 1 November 2005
- Published by Elsevier in La Presse Médicale
- Vol. 34 (19) , 1435-1444
Diagnostic et classification des hypertensions artérielles pulmonaires
- 1 May 2005
- Published by Taylor & Francis in Future Cardiology
- Vol. 1 (3) , 299-309
Bosentan Therapy for Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is characterized by the progressive increase in pulmonary vascular resistance potentially leading to right heart failure and death. Since endothelins may play a pathogenic role in the development of the disease, endothelin receptor antagonists have been proposed for the treatment of this condition. Bosentan (Tracleer), an oral nonselective ET(A)/ET(B) endothelin receptor antagonist, has been shown to improve exercise capacity, quality of life and hemodynamics of patients with PAH in short-term trials. These improvements were sustained and a long-term observational study on idiopathic PAH patients suggested a favorable effect on survival in this subset. The present report summarizes the pharmacology, clinical efficacy and safety profile of bosentan with an overview of the current therapies available for the treatment of PAH.
- 1 May 2005
- Published by Taylor & Francis in Future Cardiology
- Vol. 1 (3) , 299-309
Bosentan Therapy for Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is characterized by the progressive increase in pulmonary vascular resistance potentially leading to right heart failure and death. Since endothelins may play a pathogenic role in the development of the disease, endothelin receptor antagonists have been proposed for the treatment of this condition. Bosentan (Tracleer), an oral nonselective ET(A)/ET(B) endothelin receptor antagonist, has been shown to improve exercise capacity, quality of life and hemodynamics of patients with PAH in short-term trials. These improvements were sustained and a long-term observational study on idiopathic PAH patients suggested a favorable effect on survival in this subset. The present report summarizes the pharmacology, clinical efficacy and safety profile of bosentan with an overview of the current therapies available for the treatment of PAH.
- Open Access
- 1 June 2003
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 23 (6) , 1059-1061
Late complication of bovine pericardium patches used for lung volume reduction surgery
Lung volume reduction surgery has recently become an option for the management of patients with severe emphysema. The procedure consist of resecting non-functional lung in order to improve respiratory mechanics. Because postoperative prolonged air leakage is a serious complication of the operation, most surgeons now use staplers reinforced with bovine pericardial strips to seal the lung. We report a patient where the migration of an intact pericardium patch caused an obstructive pneumonia and recurrent hemoptysis over several years.
- 1 June 2003
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 23 (6) , 1059-1061
Open AccessLate complication of bovine pericardium patches used for lung volume reduction surgery
Lung volume reduction surgery has recently become an option for the management of patients with severe emphysema. The procedure consist of resecting non-functional lung in order to improve respiratory mechanics. Because postoperative prolonged air leakage is a serious complication of the operation, most surgeons now use staplers reinforced with bovine pericardial strips to seal the lung. We report a patient where the migration of an intact pericardium patch caused an obstructive pneumonia and recurrent hemoptysis over several years.